1,800 Seconds™ Idiopathic Pulmonary Fibrosis Management with Antifibrotic Therapy

Released On
November 30, 2018

Expires On
November 30, 2019

Media Type

Completion Time
30 minutes

Pulmonology, Radiology


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and Catamount Medical Education.


Supported by an educational grant from Boehringer Ingelheim.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, radiologists, primary care physicians, PAs, NPs, nurses, and other healthcare professionals involved in the care of patients with IPF.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Utilize guideline-driven approaches for the treatment of IPF with antifibrotic therapy
  • Interpret emerging data on the use of antifibrotic therapy in IPF


Fernando J. Martinez, MD

Chief, Division of Pulmonary and Critical Care
Bruce Webster Professor of Medicine
Joan and Sandford Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, NY

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Catamount Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Fernando J. Martinez, MD

  • Consulting fees: Biogen Idec, Sanofi-Genzyme, Genentech, TEVA Neuroscience, Novartis
  • Speakers’ Bureau: Biogen Idec, Sanofi-Genzyme, Genentech, TEVA Neuroscience, Novartis, Mallingckrodt

Method of Participation

There are no fees for participating and receiving credit for this activity. During the period November 30, 2018, through November 30, 2019, participants must:

  1. Read the learning objectives and disclosures
  2. Study the educational activity
  3. Complete the post-test and the evaluation form

To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 75% or higher), your certificate will be made available immediately. Click on "View Certificate" and print the certificate for your records. If you receive a score of 74% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities

Click here for the downloadable PDF, 1,800 Seconds™ Idiopathic Pulmonary Fibrosis Management with Antifibrotic Therapy.